The fate of phenobarbitone in children in hypothermia and at normal body temperature
Tóm tắt
Four critically injured children receiving large doses of phenobarbitone were studied during hypothermia (30°–31°C) and at normal body temperature. The volume of distribution of phenobarbitone varied from 0.79 to 1.01 litres per kg and the serum té ranged from 36.8 ± 9.4 to 86.2 ± 10.5 hrs. The percentage of dose recovered in urine in 16 days ranged from 40.5 to 65.5 pecrent: 2.7 to 12.4 percent as hydroxyphenobarbitone, 1.7 to 19.7 percent as conjugated hydroxyphenobarbitone, 6.0 to 22.4 percent as phenobarbitone-N-glucoside and 17.8 to 23.1 percent as unchanged drug. After the body temperature was allowed to return to normal the rate of excretion of metabolites increased substantially and the rate of excretion of the unchanged drug decreased markedly. It is concluded that reduction in body temperature influences the volume of distribution, rate of metabolism and excretion of phenobarbitone.
Tài liệu tham khảo
Conn, A.W., Edmonds, J.F. &Barker, G.A. Near-drowning in cold fresh water: Current treatment regimen. Can. Anaesth. Soc. J.25: 259–265 (1978).
Conn, A.W., Edmonds, J.F. &Barker, G.A. Cerebral resuscitation in near-drowning. Pediatric Clinics of North America26: 691–701 (1979).
Conn, A.W., Montes, J.E., Barker, G.A. &Edmonds, J.F. Cerebral salvage in near-drowning following neurological classification by triage. Can. Anaesth. Soc. J.27: 201–210 (1980).
Algeri, E.J. &McBay, A.J. Metabolite of phénobarbital in human urine. Science123: 183–184 (1956).
Borèus, L.O., Jalling, B. &Källberg, N. Phénobarbital metabolism in adults and in newborn infants. Acta Pacdiatr. Scand.67: 193–200 (1978).
Butler, T.C. The metabolic hydroxylation of phénobarbital. J. Pharmacol. Exp. Ther.116: 326–336 (1956).
Heimann, G. &Gladtke, E. Pharmacokinetics of phénobarbital in childhood. Eur J. Clin. Pharmacol.12: 305–310 (1977).
Horning, M.G., Butler, CM., Nowlin, J. &Hill, R.M. Minireview. Drug metabolism in the human neonate. Life Sci.16: 651–672 (1975).
Källberg, N., Agurell, S., Ericsson, O., Bucht, E., Jalling, E. Borèus, L.O. Quantitation of phénobarbital and its main metabolites in human urine. Eur. J. Clin. Pharmacol.9: 161–168 (1975).
Nau, H., Rating, D., Häuser, I., Jäger, E., Koch, S. &Helge, H. Placental transfer and pharmacokinetics of Primidone and its metabolites phénobarbital PEMA and hydroxyphenobarbital in neonates and infants of epileptic mothers. Eur. J. Clin. Pharmacol.18: 31–42 (1980).
Pitlick, W., Painter, M. &Pippenger, C. Phenobarbital pharmacokinetics in neonates. Clin. Pharmacol. Ther.23: 346–350 (1978).
Ravn-Jonsen, A., Lunding, M. &Secher, O. Excretion of phenobarbitone in urine after intake of large doses. Acta Pharmacol. Toxicol.27: 193–301 (1969).
Walson, P.D., Mimaki, T., Curless, R., Mayersohn, M. &Perrier, D. Once daily doses of phénobarbital in children. J. Pediatrics.97: 303–305 (1980).
Tang, B.K., Kalow, W. &Grey, A.A. Metabolic fate of phénobarbital in man. N-glucoside formation. Drug Metab. Dispos.7: 315–318 (1979).
Tang, B.K. &Carro-Ciampi, G. A method for the study of N-glucosidation in vitro amobarbital-N-glucoside formation in incubations with human liver. Biochem. Pharmacol.39: 2085–2088 (1980).
Kinniburgh, D.W. &Boyd, N.D. Phenytoin binding to partially purified albumin in renal disease. Clin. Pharmacol. Ther.29: 203–210 (1981).
Kalow, W., Tang, B.K., Kadar, D. &Inaba, T. Distinctive patterns of amobarbital metabolites in man. Clin. Pharmacol. Ther.24: 576–582 (1978).
Kalow, W., Endrenyi, L., Inaba, T., Kadar, D. &Tang, B.K. Pharmacogenetic investigation of amobarbital disposition. Advances in Pharmacology and Therapeutics, Clinical Pharmacology (ed. P. Duchene-Marullaz)6: 31–40 (1979).